Bringing a cosmetic product into a new market involves more than collecting certificates. The factory, formula, safety evidence, label, market notification and the business legally responsible for the product must all line up.
When a cosmetic is prepared for a new market, compliance is built layer by layer: the product must be manufactured consistently, the formula and claims must fit local rules, safety evidence must be available, the correct filing must be completed, the label must match what is actually sold, and someone must remain responsible after launch. A weakness in any layer can delay a project even when everything else is in order.
Terms such as certificate, registration, approval and notification are often used as shorthand in sourcing discussions, so it helps to separate them at the start. ISO 22716 concerns manufacturing practice. In the EU, the Cosmetic Product Safety Report (CPSR) assesses safety, the Product Information File (PIF) assembles the technical record, and CPNP is the pre-market notification system. In the United States, MoCRA facility registration and product listing are compliance steps — not FDA approval. Seeing these as different parts of one process makes it much easier to decide what the manufacturer should provide, what the brand or importer must arrange, and where legal responsibility sits.
This guide follows the order in which brands actually make compliance decisions: choose the target market, classify the product, establish manufacturing controls, build the technical file, assign responsibilities and complete the required market filings before launch.
Cosmetic Regulatory Compliance at a Glance
| Compliance Layer | What It Answers | Typical Evidence / Action | Primary Owner |
|---|---|---|---|
| Market & classification | What rules and product category apply? | Target market + intended use + claims review | Brand + regulatory lead |
| Manufacturing | Can the product be made consistently? | GMP / ISO 22716 controls | Manufacturer |
| Formula & safety | Is the formulation acceptable and safe? | Ingredient review + safety evidence | Manufacturer + brand / safety assessor |
| Technical dossier | Is the evidence assembled correctly? | PIF / CPSR / market-specific technical file | RP / brand / local responsible company |
| Notification / listing | Has the market been formally notified where required? | FDA listing / CPNP / SCPN / national notification | Responsible person / importer / notifier |
| Label & claims | Can the pack and marketing legally say what they say? | INCI, warnings, local details, claim evidence | Brand + RP / importer |
| Import & logistics | Can the shipment enter and move safely? | Commercial docs, customs docs, dangerous-goods documents if applicable | Exporter + importer / carrier |
| Post-market | Can issues be traced and managed after launch? | Adverse-event records, updates, recall / change control | Responsible legal entity + manufacturer |
1. Define the Regulatory Route Before Development
1.1 Start with the target market
Choose the destination market before finalizing the product brief. A shampoo, an eye treatment, a hair dye and a sunscreen can face different rules even when they come from the same manufacturer. Set the market and intended claims first to avoid changing an approved formula or printed label later.
1.2 Let classification and claims set the route
Classification should be settled early because the words used to describe a product can change the rules that apply to it. In the United States, therapeutic or structure/function claims can move a product into drug territory: “cleanses the scalp” and “helps hair look fuller” are very different from a claim to regrow hair, and deodorant and antiperspirant are distinct regulatory concepts. The same issue appears with dandruff, acne, SPF and other treatment-oriented positioning; a product can look like an ordinary cosmetic on the shelf while following a different regulatory pathway because of what it promises to do.
Claims also matter when they do not change the product category, because they determine what evidence the brand must hold. In the EU, Regulation (EU) No 655/2013 requires claims to meet common criteria such as legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making; ingredient properties should not be presented as finished-product performance without support. Once market, classification and claims are clear, the project can move to manufacturing control and technical evidence.
2. Build the Compliance Foundation
2.1 GMP & ISO 22716 — the manufacturing foundation
Good Manufacturing Practice (GMP) keeps cosmetic production consistent and traceable. It covers people, premises, equipment, raw materials, production records, testing, storage and corrective action. ISO 22716 gives manufacturers a practical framework for these controls.
ISO 22716:2007 remains the principal international cosmetics GMP reference (confirmed current by ISO in 2022), covering production, control, storage and shipment. On the factory floor that means defined responsibilities, trained personnel, controlled premises and equipment, raw-material and packaging controls, documented manufacturing, in-process and finished-product checks, deviation handling, complaints, recalls, internal audits, traceability and storage. Its focus is product quality, so it should not be read as a complete environmental or worker-safety standard.
Certification and compliance are easy to confuse here. A third-party ISO 22716 certificate is useful evidence for customers and some market files, but the underlying regulatory question is whether the operation actually meets applicable GMP requirements. The EU Cosmetics Regulation requires GMP and recognises harmonised standards as a route to demonstrating compliance; Great Britain likewise uses ISO 22716 as a common reference. In the United States, FDA's MoCRA GMP regulations were still rulemaking in progress at this guide's review date, 7 October 2026 — so an ISO certificate should be presented as manufacturing evidence, not U.S. product approval.
GMP establishes the manufacturing foundation. The product still needs an acceptable formula, safety evidence, suitable claims, a compliant label and the required market filing.
2.2 Build the product compliance package
Build the product file around the formula and packaging that will actually be sold. Microbiological, stability, compatibility and efficacy records then connect directly to the safety assessment, claims, artwork and notification.
A useful technical file brings together the controlled formula and INCI, specifications and COAs, relevant test results, manufacturing records, safety-assessment inputs, claim-support evidence, packaging details and approved artwork. Keep transport SDS documents separate from the cosmetic safety assessment: they answer different questions.
A practical compliance package
| Document / Evidence | What It Supports | Typical Source |
|---|---|---|
| Controlled INCI / formula | Ingredient review, safety assessment, notification | Formulator / manufacturer |
| Specifications & COA | Identity, release control, batch traceability | QC / manufacturer |
| Microbiology / stability / compatibility | Safety, shelf life, package suitability | Manufacturer + qualified laboratory |
| GMP evidence | Manufacturing control | Manufacturer / certification body |
| Claims evidence | Marketing substantiation | Laboratory / clinical study / literature as appropriate |
| Artwork & packaging data | Label review, market notification | Brand + manufacturer / packaging supplier |
2.3 Assign responsibility before filing
In an OEM/ODM project, the manufacturer owns production records and technical inputs; the brand defines commercial positioning and usually approves claims and artwork; the local importer or Responsible Person handles the legal responsibilities assigned by the destination market. Set these roles out before the first production order.
That difference is more than administrative. In the EU, the Responsible Person has statutory duties to ensure compliance and, where necessary, take corrective action, withdraw a product or arrange a recall. In the United States, the responsible person must maintain adequate safety substantiation, complete product listing and report serious adverse events. Clear agreements therefore matter whenever the formula, supplier, claims, artwork or responsible-party details may change after development begins.
The simplest way to avoid gaps is to agree the division of work before mass production: confirm the target market, regulatory classification, responsible legal entity, final INCI and formula version, agreed claims, required testing, who commissions the safety assessment, who maintains the PIF, who completes the notification or listing, who approves artwork, who supplies shipping documents, and how later changes will be controlled. A short responsibility matrix at the start of the project is more useful than resolving these questions after the goods are produced.
Responsibility Matrix for an OEM/ODM Project
| Task | Manufacturer | Brand / Product Owner | RP / Importer / Local Notifier |
|---|---|---|---|
| Formula & INCI accuracy | Primary | Approves commercial brief | Uses for assessment / filing |
| Manufacturing & batch records | Primary | Reviews as needed | May request / retain evidence |
| Product testing | Coordinates / provides | Agrees scope & claims | May require for market file |
| Safety assessment / CPSR | Provides inputs | Commissions / agrees | EU/GB RP ensures completion |
| Notification / listing | Supports technical data | May submit in some markets | Often primary legal filer |
| Artwork & claims | Technical review | Primary commercial owner | Regulatory review / market responsibility |
| Post-market events | Supports investigation | Coordinates brand response | Legal reporting duties vary by market |
Once the file and responsibilities are clear, market entry becomes a set of jurisdiction-specific tasks rather than a scramble for certificates.
3. Major Market Requirements — Five Entry Models Compared
Five practical entry models show how the same cosmetic project is handled differently in the United States, EU, Great Britain, ASEAN and Saudi Arabia.
3.1 United States — FDA & MoCRA
FDA does not pre-approve ordinary finished cosmetics. Under MoCRA, covered facilities register and renew every two years, and responsible persons submit cosmetic product listings with annual updates. Certain small businesses qualify for registration, listing and GMP exemptions, but those exemptions do not cover products that regularly contact the eye's mucous membrane, are injected or intended for internal use, or create an appearance change lasting more than 24 hours without routine consumer removal. Safety substantiation, labeling and serious-adverse-event duties still matter. Anti-dandruff shampoos, sunscreens, acne treatments and antiperspirants are regulated as drugs or drug-cosmetic combinations in the United States. California adds relevant rules including Proposition 65, consumer-product VOC limits and the restriction on intentionally added PFAS in cosmetics.
The responsible person must also hold adequate safety substantiation for the product, report serious adverse events to FDA within 15 business days, and carry an adverse-event contact (domestic address, phone or electronic contact) on the label. Two points deserve emphasis. First, registration and listing are compliance steps, not approval: in a 9 September 2026 Constituent Update, FDA clarified that it does not issue certificates or other documents verifying compliance. Presenting an FDA registration number as product approval is itself a compliance problem. Second, classification comes first: anti-dandruff shampoos, sunscreens, acne treatments and antiperspirants are drugs or drug-cosmetic combinations with additional rules. Finally, state law adds a layer — California Proposition 65 (exposure-based warnings), CARB VOC limits for relevant consumer-product categories, and a ban on intentionally added PFAS in cosmetics since 1 January 2025.
3.2 European Union — Responsible Person, CPSR, PIF & CPNP
EU compliance is a chain of responsibility and documentation. Every cosmetic placed on the EU market must have a Responsible Person (RP) established in the Union — the importer by default, unless another Union-established person is designated by written mandate and accepts in writing. The product must undergo a safety assessment (CPSR) by a suitably qualified safety assessor, and the CPSR forms part of the Product Information File (PIF), which must be kept for ten years after the last batch is placed on the market. The RP then notifies the product through the Cosmetic Products Notification Portal (CPNP) before market placement; CPNP is a notification, not an approval, and no additional national notification is required within the EU, though language and national implementation details still apply.
Three timing-sensitive points: certain nanomaterials require notification six months before market placement under Article 16 (with defined exceptions for regulated colorants, UV filters and preservatives); fragrance-allergen labeling expanded under Regulation (EU) 2023/1545 applies to products newly placed on the market from 31 July 2026 (with a transition to 31 July 2028); and REACH microplastic restrictions under Regulation (EU) 2023/2055 phase in by use category (notably 17 October 2027 for many rinse-off uses, 17 October 2029 for many leave-on uses). Formula review should map the relevant annexes — II (prohibited), III (restricted), IV (colorants), V (preservatives), VI (UV filters) — and label review should cover Article 19 items: RP name and address, country of origin, nominal content, PAO where applicable, precautions, batch, function and the ingredient list.
3.3 Great Britain — same structure, separate filing
Great Britain kept the EU-style architecture but runs its own system: a UK-established Responsible Person, a current PIF and safety report, and notification to OPSS through the Submit Cosmetic Product Notifications service (SCPN) before the product is made available. An EU CPNP notification does not cover Great Britain — the UK filing and responsible-person details must be handled separately. Northern Ireland follows the EU Cosmetics Regulation under the Windsor Framework, so NI-market products need an RP established in Northern Ireland or the EEA and notification through CPNP.
3.4 ASEAN — one directive, national filings
The ASEAN Cosmetic Directive (ACD) harmonises the technical foundations — ingredient controls, labeling, claims, GMP, safety assessment and PIF expectations — but there is no single ASEAN-wide notification. The responsible company follows each Member State's own procedure, with local-entity requirements, filing systems and validity periods that differ even when the technical file is the same. For example: Singapore (HSA/PRISM) requires a local ACRA-registered notifier and is valid for one year; Malaysia (NPRA/QUEST) requires a local Cosmetic Notification Holder or appointed agent and is valid for two years; Thailand (Thai FDA) accepts manufacturer, contract manufacturer or importer filings valid for three years. The practical approach for an OEM/ODM project is to build the formula, PIF and core artwork around the ACD first, then map filing, local-entity and label details country by country.
3.5 Saudi Arabia / GCC — national market access, not one regional certificate
Saudi Arabia illustrates the Gulf model: the project moves through a Ghad account (with the required commercial registration and authorisation), submission of the cosmetic marketing notification with manufacturer details, artwork and ingredient information, and then import clearance at the port of entry. SFDA guidance references SFDA.CO/GSO 1943:2024 safety requirements and SFDA.CO/GSO 2528:2024 claims rules; artwork, ingredient data and the manufacturer/importer relationship form part of the practical submission package. Other GCC markets, including the UAE, operate their own procedures, so a Saudi notification is not GCC-wide approval. Halal certification may be commercially important for certain markets, channels or brand positions, but it serves a different purpose from statutory notification and safety compliance.
3.6 The five models side by side
| Market | Entry Model | Core Compliance File / System | Critical Watch-Out |
|---|---|---|---|
| United States | Facility registration + product listing under MoCRA | Safety substantiation records + FDA registration/listing | Registration/listing is not FDA approval; claims can trigger drug rules |
| European Union | Responsible Person + CPNP notification | CPSR + PIF + GMP evidence | Label / ingredient / claims requirements; 2026 fragrance-allergen transition |
| Great Britain | UK Responsible Person + SCPN notification | PIF + safety report | EU CPNP does not cover GB; Northern Ireland differs |
| ASEAN | National notification under harmonised ACD framework | PIF + ACD ingredient / label / claims compliance | No single notification covers every Member State |
| Saudi Arabia | SFDA marketing notification/listing + import clearance | Artwork + ingredient data + manufacturer/importer documentation | Ghad service; GSO/SFDA safety and claims rules; not a GCC-wide approval |
4. Labeling & Artwork — Turning Compliance Into the Finished Pack
4.1 One formula may need several label versions
One formula can serve several markets, but the finished label may need different languages, responsible-party information, ingredient declarations, warnings, quantities and contact details. Review the market-specific artwork before print approval; reprinting a finished run is far more costly than correcting a PDF.
4.2 Keep artwork under change control
Artwork must stay connected to the technical file after launch. A formula change, fragrance change, supplier change, claim revision, address change or new regulatory restriction can make an existing label obsolete even when the product name stays the same. A disciplined workflow links the current formula version, test reports, safety assessment, notification record and approved artwork, so one part of the file is not updated while the others quietly fall behind.
5. Export Documents & Special Product Risks
5.1 Market-access documents and shipping documents serve different purposes
Market-access documents explain why the cosmetic may be sold; shipping documents identify the cargo and support customs clearance. Depending on the shipment, the pack can include a commercial invoice, packing list, origin documentation, COA, SDS, Free Sale Certificate or authorizations requested by the importer.
5.2 Products and certificates that need extra checks
Some formats add a second layer of logistics risk. Pressurised aerosols and certain high-alcohol or otherwise hazardous formulations may be classified as dangerous goods for transport; air and sea shipments must then follow the applicable framework (IATA DGR for air, IMDG Code for sea) together with carrier and destination requirements. A cosmetic can be fully compliant as a consumer product and still be delayed in transit if its dangerous-goods classification, packaging, marks or shipping documents are wrong.
Separate three things when budgeting for certificates: statutory market-entry documents, importer or retailer requirements, and voluntary brand-positioning schemes such as organic or vegan certification. A Free Sale Certificate or Halal certificate serves a different purpose from cosmetic notification or GMP.
6. From Development to Launch
6.1 A practical pre-launch compliance workflow
Use one linked launch workflow: define the destination and classification; freeze the formula and claims; complete testing and safety work; approve the responsible-party arrangement; file the required notification or listing; print the approved artwork; and book compliant transport. Update the dependent records when anything material changes.
6.2 Regulatory timing checkpoints
| Checkpoint | Timing to build into the launch plan |
|---|---|
| U.S. facility registration | Renew every two years; use the facility renewal date shown in FDA systems |
| U.S. cosmetic product listing | Update annually and when required information changes |
| U.S. serious adverse event | Report to FDA within 15 business days |
| EU nanomaterial notification | Where Article 16 applies, notify 6 months before placing the product on the market |
| EU / GB / ASEAN market notification | Complete before market placement or supply; confirm country/service lead times for the specific filing route |
6.3 Where compliance projects commonly lose time
Projects tend to lose time at a small number of handover points — less about obscure regulation than about doing the right work in the wrong order:
- Treating an FDA registration number as product approval, which creates a second compliance problem in the marketing itself.
- Printing final packaging before the destination-market review, turning a small correction (address, warning, local-language field, allergen declaration) into a full reprint.
- Reusing an EU file for Great Britain, or treating one ASEAN notification as regional coverage, leaving the product without the separate filing or local responsible entity the destination still requires.
- Changing the formula, fragrance or claim set after the safety assessment or notification, so the dossier, filing and artwork describe different versions of the same product.
- Moving from cosmetic appearance or cleansing claims into therapeutic positioning, which can change the product category and trigger a different evidence and filing route.
- Booking an aerosol or other regulated shipment as ordinary cargo, delaying a market-ready product when dangerous-goods classification and carrier rules were not addressed.
The common failure is broken handover: the artwork, safety file, notification and physical shipment describe different versions of the project. Keep them under one change-control process.
7. What to Expect from a Compliance-Ready OEM/ODM Partner
7.1 What the manufacturer should be able to provide
The OEM/ODM manufacturer's value is reliable technical execution: controlled INCI and formula records, batch COAs, relevant tests, GMP evidence, packaging specifications and change-control records. The brand and local regulatory partners use those records for safety assessment, filings and market supervision.
Start the supplier discussion with four details: product type, destination market, intended claims and proposed formula or packaging changes. Those answers tell both sides what evidence and documents the launch needs.
7.2 The bottom line
Compliance decisions belong at the beginning of development, not after production. Set the target market and claims early, define who is responsible, and keep the file, artwork and shipment matched to the actual product.
Frequently Asked Questions
Does FDA approve cosmetics before sale? FDA does not pre-approve ordinary finished cosmetic products. Certain color additives have approval requirements, and products regulated as drugs follow different rules. MoCRA registration and listing are not product approval.
What is the difference between ISO 22716, CPSR, PIF and CPNP? They sit at different points in the process: ISO 22716 is a cosmetics GMP guideline for manufacturing; the CPSR is the EU safety report; the PIF is the broader technical file containing the CPSR and other required information; CPNP is the EU pre-market notification system. Each serves a different purpose, so none replaces the others.
Is CPNP valid in Great Britain? Not for Great Britain, which uses its own SCPN system and a UK-established Responsible Person. Northern Ireland follows the EU Cosmetics Regulation under the Windsor Framework, so NI products require an RP established in Northern Ireland or the EEA and notification through CPNP.
Does one ASEAN notification cover all ASEAN countries? No. The ACD harmonises technical requirements, but the responsible company still follows the notification procedure of each Member State in which the product is marketed.
Does every cosmetic sold in the Middle East need Halal certification? Not necessarily. Halal requirements and expectations vary by market, channel and brand positioning, and should be assessed separately from statutory notification and safety requirements.
What documents should an OEM cosmetic manufacturer provide? Commonly: controlled formula and INCI information, specifications, COAs, relevant test data, GMP evidence, packaging information, claim-support documentation, and the technical inputs needed for safety assessment and market filing. The exact package depends on the product and destination.
Can the same cosmetic label be used worldwide? A shared core design is possible, but the final label often needs market-specific details. Language, responsible-party information, warnings, ingredient declarations, quantity formats and claim rules differ, so artwork should be reviewed for each target market before printing.
Do aerosol cosmetics require extra export compliance? Often, yes. If the finished product is classified as dangerous goods for transport, it must meet the applicable air or sea transport requirements in addition to the cosmetic rules governing sale in the destination market.
Key Regulations, Standards & Official Sources
Official sources supporting the principal requirements in this guide. Regulations, guidance and filing systems change, so check the current version before a product, label or submission is finalized. Online sources last reviewed 7 October 2026.
- ISO 22716:2007 — Cosmetics GMP Guidelines: https://www.iso.org/standard/36437.html
- FDA — Modernization of Cosmetics Regulation Act of 2022 (MoCRA): https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra
- FDA — Registration & Listing of Cosmetic Product Facilities and Products: https://www.fda.gov/cosmetics/registration-listing-cosmetic-product-facilities-and-products
- FDA — Cosmetics Labeling Guide: https://www.fda.gov/cosmetics/cosmetics-labeling-regulations/cosmetics-labeling-guide
- FDA — Is It a Cosmetic, a Drug, or Both?: https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
- EU — Regulation (EC) No 1223/2009 on cosmetic products (Articles 4, 5, 11, 13, 16, 19): https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32009R1223
- EU — Cosmetic Products Notification Portal (CPNP): https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-product-notification-portal_en
- EU — Regulation (EU) No 655/2013 on common criteria for cosmetic claims: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32013R0655
- European Commission — Fragrance allergens labelling: https://single-market-economy.ec.europa.eu/sectors/cosmetics/cosmetic-products-specific-topics/fragrance-allergens-labelling_en
- GOV.UK — Making cosmetic products available to consumers in Great Britain: https://www.gov.uk/guidance/making-cosmetic-products-available-to-consumers-in-great-britain
- ASEAN — Key Documents for the ASEAN Cosmetic Directive: https://asean.org/our-communities/economic-community/standards-technical-regulations-and-conformity-assessment-procedures/key-documents-publications/
- Singapore HSA — ASEAN Cosmetic Directive: https://www.hsa.gov.sg/cosmetic-products/asean-cosmetic-directive/
- Saudi FDA — Cosmetic Product Marketing Notification / Ghad: https://sfda.gov.sa/en/node/307
- California OEHHA — Proposition 65 for businesses: https://oehha.ca.gov/proposition-65/businesses-and-proposition-65
- California ARB — Consumer Products Regulation: https://ww2.arb.ca.gov/our-work/programs/consumer-products-enforcement/consumer-products-regulation
